Ratings for Healthpeak Properties (NYSE:DOC) were provided by 7 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 0 | 3 | 4 | 0 | 0 |
| Last 30D | 0 | 0 | 0 | 0 | 0 |
| 1M Ago | 0 | 1 | 2 | 0 | 0 |
| 2M Ago | 0 | 1 | 1 | 0 | 0 |
| 3M Ago | 0 | 1 | 1 | 0 | 0 |
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $18.71, with a high estimate of $21.00 and a low estimate of $17.00. Experiencing a 7.97% decline, the current average is now lower than the previous average price target of $20.33.

The perception of Healthpeak Properties by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| James Kammert | Evercore ISI Group | Lowers | Outperform | $19.00 | $21.00 |
| John Kilichowski | Wells Fargo | Lowers | Equal-Weight | $18.00 | $19.00 |
| Julien Blouin | Goldman Sachs | Announces | Neutral | $17.00 | - |
| Jonathan Petersen | Jefferies | Lowers | Hold | $17.00 | $21.00 |
| James Kammert | Evercore ISI Group | Lowers | Outperform | $21.00 | $22.00 |
| John Kilichowski | Wells Fargo | Raises | Equal-Weight | $19.00 | $18.00 |
| Amanda Sweitzer | Baird | Lowers | Outperform | $20.00 | $21.00 |
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Healthpeak Properties's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
Stay up to date on Healthpeak Properties analyst ratings.
Healthpeak owns a diversified healthcare portfolio of approximately 700 in-place properties spread across mainly medical office and life science assets, plus a handful of senior housing, hospital, and skilled nursing/post-acute care assets, as well.
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: Healthpeak Properties displayed positive results in 3M. As of 31 December, 2025, the company achieved a solid revenue growth rate of approximately 3.07%. This indicates a notable increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Real Estate sector.
Net Margin: Healthpeak Properties's net margin is impressive, surpassing industry averages. With a net margin of 15.83%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Healthpeak Properties's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 1.51% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 0.57%, the company showcases effective utilization of assets.
Debt Management: Healthpeak Properties's debt-to-equity ratio is below the industry average. With a ratio of 1.35, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
This article was generated by Benzinga's automated content engine and reviewed by an editor.